Patient Selection for Left Ventricular Assist Devices

Congestive Heart Failure

Volumn 17, Issue 5, 2011, Pages 227-234

  Khazanie, Prateeti ^a   Rogers, Joseph G ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSISTED CIRCULATION; CARDIOVASCULAR SYSTEM; CLINICAL EVALUATION; HEART RIGHT VENTRICLE FUNCTION; HEART SEPTUM DEFECT; HEMATOLOGY; HUMAN; KIDNEY FUNCTION; LEFT VENTRICULAR ASSIST DEVICE; LIVER FUNCTION; LUNG FUNCTION; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SOCIAL PSYCHOLOGY; SURGICAL RISK; TREATMENT INDICATION; VALVULAR HEART DISEASE;

HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80052659109     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00236.x     Document Type: Review

References (46)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
2. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-187.
3. Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320-324.
4. Felker GM, Rogers JG. Same bridge, new destinations: rethinking paradigms for mechanical cardiac support in heart failure. J Am Coll Cardiol. 2006;47:930-932.
5. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30:115-123.
6. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg. 2007;133:689-695.
7. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation. 2009;120:2352-2357.
8. Center for Medicare & Medicaid Services. Medicare national coverage determinations manual. 2010. Accessed July 7, 2011.
9. Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation. 1995;92:II169-II173.
10. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29:1-10.
11. Adamson RM, Stahovich M, Chillcott S, et al. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device. J Am Coll Cardiol. 2011;57:2487-2495.
12. Topilsky Y, Pereira NL, Shah DK, et al. LVAD therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011;4:266-275.
13. Mokashi SA, Schmitto JD, Lee LS, et al. Ventricular assist device in patients with prosthetic heart valves. Artif Organs. 2010;34:1030-1034.
14. John R, Mantz K, Eckman P, et al. Aortic valve pathophysiology during left ventricular assist device support. J Heart Lung Transplant. 2010;29:1321-1329.
15. Rose AG, Connelly JH, Park SJ, et al. Total left ventricular outflow tract obstruction due to left ventricular assist device-induced sub-aortic thrombosis in 2 patients with aortic valve bioprosthesis. J Heart Lung Transplant. 2003;22:594-599.
16. Feldman CM, Silver MA, Sobieski MA, Slaughter MS. Management of aortic insufficiency with continuous flow left ventricular assist devices: bioprosthetic valve replacement. J Heart Lung Transplant. 2006;25:1410-1412.
17. Pal JD, Klodell CT, John R, et al. Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation. 2009;120:S215-S219.
18. Potapov EV, Stepanenko A, Dandel M, et al. Tricuspid incompetence and geometry of the right ventricle as predictors of right ventricular function after implantation of a left ventricular assist device. J Heart Lung Transplant. 2008;27:1275-1281.
19. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
20. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-896.
21. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139:1316-1324.
22. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk scorea pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163-2172.
23. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the Post-REMATCH era: implications for patient selection. Circulation. 2007;116:497-505.
24. Schenk S, McCarthy PM, Blackstone EH, et al. Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome. J Thorac Cardiovasc Surg. 2006;131:447-454.
25. Estep JD, Stainback RF, Little SH, et al. The role of echocardiography and other imaging modalities in patients with left ventricular assist devices. JACC Cardiovasc Imaging. 2010;3:1049-1064.
26. Nakatani S, Thomas JD, Savage RM, et al. Prediction of right ventricular dysfunction after left ventricular assist device implantation. Circulation. 1996;94:II216-II221.
27. Fukamachi K, McCarthy PM, Smedira NG, et al. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg. 1999;68:2181-2184.
28. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation. 2002;106:I198-I202.
29. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25:1-6.
30. Puwanant S, Hamilton KK, Klodell CT, et al. Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant. 2008;27:1102-1107.
31. Fitzpatrick JR 3rd, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27:1286-1292.
32. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 2006;81:1745-1751.
33. Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg. 2009;87:1072-1078.
34. Masai T, Sawa Y, Ohtake S, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg. 2002;73:549-555.
35. Deng MC, Loebe M, El-Banayosy A, et al. Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome. Circulation. 2001;103:231-237.
36. Crow S, Chen D, Milano CA, et al. Acquired von Willebrand syndrome in continuous flow left ventricular assist device recipients. Ann Thorac Surg. 2010;90:1263-1269.
37. Cervini P, Park SJ, Shah DK, et al. Carotid Doppler ultrasound findings in patients with left ventricular assist devices. Ultrasound Q. 2010;26:255-261.
38. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle. 2010;1:1-5.
39. Anker S, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050-1053.
40. Holdy K, Dembitsky W, Eaton L, et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant. 2005;24:1690-1696.
41. Wray J, Hallas CN, Banner NR. Quality of life and psychological well-being during and after left ventricular assist device support. Clin Transplant. 2007;21:622-627.
42. Eshelman AK, Mason S, Nemeh H, Williams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev. 2009;14:21-28.
43. Gracin N, Johnson MR, Spokas D, et al. The use of APACHE II scores to select candidates for left ventricular assist device placement. Acute physiology and chronic health evaluation. J Heart Lung Transplant. 1998;17:1017-1023.
44. Schaffer JM, Allen JG, Weiss ES, et al. Evaluation of risk indices in continuous-flow left ventricular assist device patients. Ann Thorac Surg. 2009;88:1889-1896.
45. Matthews JC, Pagani FD, Haft JW, et al. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation. 2010;121:214-220.
46. Klotz S, Vahlhaus C, Riehl C, et al. Pre-operative prediction of post-VAD implant mortality using easily accessible clinical parameters. J Heart Lung Transplant. 2010;29:45-52.